Sign in

CIK 0001649989

  • Non-accelerated filer
  • Smaller reporting company

Outlook Therapeutics, Inc.

Sign in to watch
Ticker
OTLK
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Sep 30
Incorporated
DE
Entity type
Operating
EIN
383982704
Phone
+1 609-619-3990
Business address
111 S. WOOD AVENUE, UNIT #100, ISELIN, NJ, 08830
Former names
Oncobiologics, Inc.
  1. 4 Grant or award Director acquired 12,754,766 shares (grant or award)
  2. 4 Derivatives Options or other derivatives
  3. 3 Insider Initial Statement of Ownership
  4. 4 Derivatives Options or other derivatives
  5. 3 Insider Initial Statement of Ownership
  6. 4 Derivatives Options or other derivatives
  7. 3 Insider Initial Statement of Ownership
  8. 4 Open-market sale President & CEO sold 114,677 shares at an average $1.17 ($134,067)
  9. 4 Open-market sale VP, Regulatory Affairs sold 16,170 shares at $1.13 ($18,272)
  10. 4 Open-market sale Chief Medical Officer sold 26,165 shares at $1.13 ($29,566)
  11. 4 Open-market sale SVP Bus. Strat. & Dev. sold 15,705 shares at $1.13 ($17,747)
  12. 4 Open-market sale CFO and Secretary sold 26,165 shares at $1.13 ($29,566)
  13. 4 Open-market sale President & CEO sold 104,131 shares at an average $1.15 ($119,325)
  14. 4 Open-market sale VP, Regulatory Affairs sold 7,660 shares at an average $1.15 ($8,778)
  15. 4 Derivatives Options or other derivatives
  16. 4 Derivatives Options or other derivatives
  17. 4 Derivatives Options or other derivatives
  18. 4 Derivatives Options or other derivatives
  19. 3 Insider Initial Statement of Ownership
  20. 3 Insider Initial Statement of Ownership

Page 13 of 16 · 305 filings